Stay updated on PF-06463922 ALK/ROS1 Inhibitor Clinical Trial
Sign up to get notified when there's something new on the PF-06463922 ALK/ROS1 Inhibitor Clinical Trial page.

Latest updates to the PF-06463922 ALK/ROS1 Inhibitor Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAn NIH-wide banner announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision number also changes from v3.7.1 to v3.7.2.SummaryDifference0.3%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page's revision label changed from Revision: v3.6.6 to Revision: v3.7.0, indicating a software update to the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check57 days agoChange DetectedFooter revision label updated from v3.6.5 to v3.6.6. This indicates a minor software update to the site interface.SummaryDifference0.0%

- Check78 days agoChange DetectedRevision: v3.6.5 replaces the previous v3.6.4, updating the page's displayed site revision. This signals a new build/version of the ClinicalTrials.gov interface without altering the underlying study records.SummaryDifference0.0%

- Check93 days agoChange DetectedThe page history now shows the latest revision as v3.6.4, replacing the previous v3.6.3, indicating the record has been updated to a newer version. No study data or public content changes are reflected in this entry.SummaryDifference0.0%

Stay in the know with updates to PF-06463922 ALK/ROS1 Inhibitor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06463922 ALK/ROS1 Inhibitor Clinical Trial page.